Participants using tirzepatide 15 mg lost a mean of 22.5% of body weight versus 2.4% in the placebo group over 72 weeks - the largest weight reduction ever documented in a Phase 3 placebo-controlled trial for a pharmacological weight management agent at the time of publication, a figure that represented a significant outcome in the drug class at the time of publication
dnDSA were requested prospectively annually in all subjects or before any episode of renal function deterioration
How we use the collected information and with whom it may be shared
The most common adverse events are transient gastrointestinal disturbances (nausea, diarrhea, constipation, vomiting) occurring predominantly during dose escalation
In rodents, CR delays the onset of cancer, atherosclerosis, and diabetes, and typically increases lifespan (by 15% in mice and by 30% in rats) (Swindell, 2012)